FDA and CMS move to speed custom gene therapies for rare diseases
Published
New FDA draft guidance would let makers of personalized gene-editing treatments add new patient-specific versions without new trials if they stay within set limits. CMS is also opening its Medicaid gene therapy payment model, now used for sickle cell disease, to therapies for other conditions.
Source: Becker's Hospital Review
This is a plain-language summary. Read the original source for full details.